Loading
A phase 3 trial of Sevabertinib, Pembrolizumab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bayer, now recruiting.
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) is a phase 3 interventional study registered as NCT06452277 by Bayer, with 444 participants planned, started 2024-08-28 and due to reach its primary completion in 2027-10-28. Interventions recorded: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed. Conditions listed: Advanced Non-small Cell Lung Cancer, HER2 Mutation. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Sevabertinib, Bayer, HER2-mutant non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/